NCT07282015

Real-world Secukinumab Outcomes in Canadian HS Patients

A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 142 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Conditions

• Hidradenitis Suppurativa

Timeline

• Start date: 2025-12-12
• Primary completion: 2028-02-11
• Completion: 2028-02-11
• First posted: 2025-12-15
• Last updated: 2026-04-15

Locations

11 sites across 1 country: Canada